Question · asked by 1 review

Cetirizine 10 mg/d vs placebo (4‐week intervention): Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period

Population
adults with eczema
Intervention
Cetirizine 10 mg/d
Comparison
placebo (4‐week intervention)
Outcome
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period

Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Cetirizine 10 mg/d vs placebo (4‐week intervention)
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane Headline outcomes only
RR 1.11 [0.5, 2.45]1 study · 84 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema
2019 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.